SWOG clinical trial number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)

Open
Phase
Abbreviated Title
Triple-Switch
Status Notes
CCTG-PR26 has been endorsed and activated by SWOG, effective 01/30/2025. CCTG-PR26 was activated by CCTG, effective 01/30/2025..
Activated
01/30/2025
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Genitourinary Cancer

Treatment

Docetaxel Abiraterone Acetate Enzalutamide Apalutamide Darolutamide

Other Study Materials

Eligibility Criteria Expand/Collapse

Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).

Publication Information Expand/Collapse

2026

TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924)

Ong M ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs TPS5149 poster 235a; J Clin Oncol 44, 2026 (suppl 16; abstr TPS5149) DOI: 10.1200/JCO.2026.44.16_suppl.TPS5149

2025

TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized Phase III Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response

M Ong;A Sokolova;S Hotte;T Dorff;K Chi;A Wyatt;A Goldkorn;M Kolinsky;M Brundage;A Ndika;S Lerner;W Parulekar;K Ding;M Jafri ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), tip; Abstract # TPS5129 Poster Bd # 318b

Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response

A Sokolova;M Ong;S Hotte;T Dorff;K Chi;A Wyatt;A Goldkorn;M Kolinsky;M Brundage;A Ndika;S Lerner;W Parulekar;K Ding;M Jafri Prostate Cancer Foundation annual meeting (October 23-25, 2025, Carlsbad, CA)

Other Clinical Trials

SWOG Clinical Trial Number
S2419

Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
26%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase